Clinical Trial Update: Gene Therapy(FT-003) for Wet AMD [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating gene therapy FT-003 for neovascular age-related macular degeneration and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• FT-003

Snippet

Sponsor: Frontera Therapeutics | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: RECRUITING